All In Biotech

NDA 204447 · Takeda Pharms USA

Trintellix

Vortioxetine Hydrobromide · Oral

Novel

Last checked: Nov 20, 2026Latest source record: Aug 23, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2013

Sep 30, 2013

Approved uses

7

Original approval plus efficacy supplements

Registered trials

2

1 Phase 3, 0 recruiting

FAERS reports

17,188

8,272 serious, 1,016 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behavior in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors [see Warnings and Precautions (5.1) ] . TRINTELLIX is not approved for use in pediatric patients [see Use in Specific Populations (8.4) ] . WARNING: SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning. Increased risk of suicidal thinking and behavior in pediatric and young adult patients taking antidepressants. Closely monitor for worsening and emergence of suicidal thoughts and behaviors ( 5.1 ). TRINTELLIX is not approved for use in pediatric patients ( 8.4 ).

What it is approved for

From the label in effect Apr 23, 2026.

TRINTELLIX is indicated for the treatment of major depressive disorder (MDD) in adults. TRINTELLIX is indicated for the treatment of major depressive disorder (MDD) in adults ( 1 , 14 ).

Mechanism: The mechanism of the antidepressant effect of vortioxetine is not fully understood, but is thought to be related to its enhancement of serotonergic activity in the CNS through inhibition of the reuptake of serotonin (5-HT). It also has several other activities including 5-HT3 receptor antagonism and 5-HT1A receptor agonism. The contribution of these activities to vortioxetine's antidepressant effect has not been established.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

4 products under this application
  • TRINTELLIX · VORTIOXETINE HYDROBROMIDE EQ 10MG BASE · TABLET, ORAL · Prescription
  • TRINTELLIX · VORTIOXETINE HYDROBROMIDE EQ 15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued
  • TRINTELLIX · VORTIOXETINE HYDROBROMIDE EQ 5MG BASE · TABLET, ORAL · Prescription
  • TRINTELLIX · VORTIOXETINE HYDROBROMIDE EQ 20MG BASE · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Vortioxetine Hydrobromide" as an intervention, any sponsor and status, largest first.

All 2 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • nausea2,284
  • fatigue1,225
  • drug ineffective1,165
  • headache1,075
  • anxiety1,053
  • vomiting1,036
  • suicidal ideation969
  • off label use948
  • insomnia942
  • dizziness904
  • diarrhoea850
  • pruritus806

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20121
201410
2015116
20161,444
20172,154
20181,866
20192,005
20201,668
20211,553
20221,419
20231,274
20241,442
20251,323
2026913

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Trintellix (Vortioxetine Hydrobromide)

2024 spending

$392M

Beneficiaries

100,706

610,008 claims

Per beneficiary

$3,897

$16.06 per unit

View as table
YearSpending
2020$314,974,935
2021$337,760,606
2022$366,780,643
2023$389,714,302
2024$392,486,138

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2 on PubMed

Sponsor: Takeda

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.